IPO registrations (S-1, F-1) · Registrants
Stablecoin Development Corp
- SEC CIK
- 1389545 · filings on EDGAR ↗
- Name on the registration
- NovaBay Pharmaceuticals, Inc.
- Former names
- NovaBay Pharmaceuticals, Inc. (2007–2026)
- Registration
- Form S-1, first filed 2007-02-14, last 2024-07-25; 13 initial registrations, 13 amendments
- Outcome
- Final prospectus filed 2007-10-26; declared effective 2007-10-24
- Industry (SIC)
- Finance Services 6199
- Incorporated in
- DE
- Business address
- 222 LAKEVIEW AVE, SUITE 800, West Palm Beach, FL 33401
- EIN
- 68-0454536
- Ticker
- SDEV (NYSE)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Stablecoin Development Corp on the corporate pages
On this site
- Business registration: NOVABAY PHARMACEUTICALS, INC. EXACT (EIN (EXACT, as the state registration reports it))
- Business registration: STABLECOIN DEVELOPMENT CORPORATION EXACT (EIN (EXACT, as the state registration reports it))
- Form 5500 plan sponsor: NOVABAY PHARMACEUTICALS INC EXACT (EIN (EXACT))
- Form D issuer: NovaBay Pharmaceuticals, Inc. EXACT (CIK (EXACT))
- SEC filer: NovaBay Pharmaceuticals, Inc. EXACT (CIK (EXACT))
- Person page: Harry F Hixson Jr Phd Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
- Person page: Robert R Tufts Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 55
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2007-02-14 | S-1 | S-1 (registration) | NovaBay Pharmaceuticals, Inc. | 0001193125-07-032009 ↗ |
| 2007-03-30 | S-1/A | S-1/A (amendment) | NovaBay Pharmaceuticals, Inc. | 0001193125-07-070391 ↗ |
| 2007-04-18 | S-1/A | S-1/A (amendment) | NovaBay Pharmaceuticals, Inc. | 0001193125-07-083958 ↗ |
| 2007-05-29 | S-1/A | S-1/A (amendment) | NovaBay Pharmaceuticals, Inc. | 0001193125-07-123999 ↗ |
| 2007-07-05 | S-1/A | S-1/A (amendment) | NovaBay Pharmaceuticals, Inc. | 0001193125-07-150026 ↗ |
| 2007-08-10 | S-1/A | S-1/A (amendment) | NovaBay Pharmaceuticals, Inc. | 0001193125-07-178794 ↗ |
| 2007-09-04 | S-1/A | S-1/A (amendment) | NovaBay Pharmaceuticals, Inc. | 0001193125-07-194886 ↗ |
| 2007-09-20 | S-1/A | S-1/A (amendment) | NovaBay Pharmaceuticals, Inc. | 0001193125-07-204432 ↗ |
| 2007-10-24 | S-1/A | S-1/A (amendment) | NovaBay Pharmaceuticals, Inc. | 0001193125-07-224329 ↗ |
| 2007-10-24 | EFFECT | EFFECT (declared effective) | NovaBay Pharmaceuticals, Inc. | 9999999995-07-004199 ↗ |
| 2007-10-26 | 424B4 | 424B4 (final prospectus) | NovaBay Pharmaceuticals, Inc. | 0001193125-07-227111 ↗ |
| 2009-08-05 | EFFECT | EFFECT (declared effective) | NovaBay Pharmaceuticals, Inc. | 9999999995-09-002166 ↗ |
| 2009-08-11 | EFFECT | EFFECT (declared effective) | NovaBay Pharmaceuticals, Inc. | 9999999995-09-002231 ↗ |
| 2010-07-09 | EFFECT | EFFECT (declared effective) | NovaBay Pharmaceuticals, Inc. | 9999999995-10-002084 ↗ |
| 2012-05-01 | EFFECT | EFFECT (declared effective) | NovaBay Pharmaceuticals, Inc. | 9999999995-12-001364 ↗ |
| 2015-04-20 | EFFECT | EFFECT (declared effective) | NovaBay Pharmaceuticals, Inc. | 9999999995-15-000929 ↗ |
| 2015-07-10 | EFFECT | EFFECT (declared effective) | NovaBay Pharmaceuticals, Inc. | 9999999995-15-001892 ↗ |
| 2016-06-20 | EFFECT | EFFECT (declared effective) | NovaBay Pharmaceuticals, Inc. | 9999999995-16-004946 ↗ |
| 2016-06-20 | EFFECT | EFFECT (declared effective) | NovaBay Pharmaceuticals, Inc. | 9999999995-16-004947 ↗ |
| 2017-12-15 | S-1 | S-1 (registration) | NovaBay Pharmaceuticals, Inc. | 0001437749-17-020791 ↗ |
| 2019-04-12 | EFFECT | EFFECT (declared effective) | NovaBay Pharmaceuticals, Inc. | 9999999995-19-000700 ↗ |
| 2019-07-31 | EFFECT | EFFECT (declared effective) | NovaBay Pharmaceuticals, Inc. | 9999999995-19-001772 ↗ |
| 2019-09-12 | EFFECT | EFFECT (declared effective) | NovaBay Pharmaceuticals, Inc. | 9999999995-19-002084 ↗ |
| 2019-10-25 | S-1 | S-1 (registration) | NovaBay Pharmaceuticals, Inc. | 0001437749-19-020651 ↗ |
| 2019-11-05 | EFFECT | EFFECT (declared effective) | NovaBay Pharmaceuticals, Inc. | 9999999995-19-002485 ↗ |
| 2020-02-10 | EFFECT | EFFECT (declared effective) | NovaBay Pharmaceuticals, Inc. | 9999999995-20-000297 ↗ |
| 2020-05-15 | S-1 | S-1 (registration) | NovaBay Pharmaceuticals, Inc. | 0001437749-20-011044 ↗ |
| 2020-05-22 | EFFECT | EFFECT (declared effective) | NovaBay Pharmaceuticals, Inc. | 9999999995-20-001245 ↗ |
| 2020-09-01 | EFFECT | EFFECT (declared effective) | NovaBay Pharmaceuticals, Inc. | 9999999995-20-002335 ↗ |
| 2021-04-07 | EFFECT | EFFECT (declared effective) | NovaBay Pharmaceuticals, Inc. | 9999999995-21-001329 ↗ |
| 2021-12-01 | S-1 | S-1 (registration) | NovaBay Pharmaceuticals, Inc. | 0001437749-21-027634 ↗ |
| 2021-12-10 | EFFECT | EFFECT (declared effective) | NovaBay Pharmaceuticals, Inc. | 9999999995-21-004650 ↗ |
| 2022-02-04 | S-1 | S-1 (registration) | NovaBay Pharmaceuticals, Inc. | 0001437749-22-002525 ↗ |
| 2022-02-10 | EFFECT | EFFECT (declared effective) | NovaBay Pharmaceuticals, Inc. | 9999999995-22-000410 ↗ |
| 2022-10-25 | S-1 | S-1 (registration) | NovaBay Pharmaceuticals, Inc. | 0001437749-22-024692 ↗ |
| 2022-10-31 | EFFECT | EFFECT (declared effective) | NovaBay Pharmaceuticals, Inc. | 9999999995-22-003175 ↗ |
| 2022-12-09 | S-1 | S-1 (registration) | NovaBay Pharmaceuticals, Inc. | 0001437749-22-028819 ↗ |
| 2022-12-15 | EFFECT | EFFECT (declared effective) | NovaBay Pharmaceuticals, Inc. | 9999999995-22-003561 ↗ |
| 2022-12-30 | S-1 | S-1 (registration) | NovaBay Pharmaceuticals, Inc. | 0001437749-22-029932 ↗ |
| 2023-03-31 | S-1/A | S-1/A (amendment) | NovaBay Pharmaceuticals, Inc. | 0001437749-23-008887 ↗ |
| 2023-05-17 | S-1/A | S-1/A (amendment) | NovaBay Pharmaceuticals, Inc. | 0001437749-23-014949 ↗ |
| 2023-05-22 | EFFECT | EFFECT (declared effective) | NovaBay Pharmaceuticals, Inc. | 9999999995-23-001493 ↗ |
| 2023-05-31 | S-1 | S-1 (registration) | NovaBay Pharmaceuticals, Inc. | 0001437749-23-016278 ↗ |
| 2023-05-31 | S-1 | S-1 (registration) | NovaBay Pharmaceuticals, Inc. | 0001437749-23-016284 ↗ |
| 2023-06-08 | EFFECT | EFFECT (declared effective) | NovaBay Pharmaceuticals, Inc. | 9999999995-23-001689 ↗ |
| 2023-06-08 | EFFECT | EFFECT (declared effective) | NovaBay Pharmaceuticals, Inc. | 9999999995-23-001690 ↗ |
| 2024-06-20 | S-1 | S-1 (registration) | NovaBay Pharmaceuticals, Inc. | 0001437749-24-020830 ↗ |
| 2024-06-21 | S-1 | S-1 (registration) | NovaBay Pharmaceuticals, Inc. | 0001437749-24-021005 ↗ |
| 2024-06-27 | EFFECT | EFFECT (declared effective) | NovaBay Pharmaceuticals, Inc. | 9999999995-24-002005 ↗ |
| 2024-07-10 | S-1/A | S-1/A (amendment) | NovaBay Pharmaceuticals, Inc. | 0001437749-24-022434 ↗ |
| 2024-07-15 | S-1/A | S-1/A (amendment) | NovaBay Pharmaceuticals, Inc. | 0001437749-24-022700 ↗ |
| 2024-07-25 | S-1/A | S-1/A (amendment) | NovaBay Pharmaceuticals, Inc. | 0001437749-24-023391 ↗ |
| 2024-07-25 | EFFECT | EFFECT (declared effective) | NovaBay Pharmaceuticals, Inc. | 9999999995-24-002275 ↗ |
| 2024-07-29 | 424B4 | 424B4 (final prospectus) | NovaBay Pharmaceuticals, Inc. | 0001437749-24-023641 ↗ |
| 2025-11-26 | EFFECT | EFFECT (declared effective) | NovaBay Pharmaceuticals, Inc. | 9999999995-25-003396 ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Cashion Charles | Director | 35 | 2007–2015 | ||
| Dailley Anthony | Director | 35 | 2007–2014 | ||
| Freiman Paul E. | Director | 52 | 2007–2026 | ||
| Khosrovi Behzad | Officer | SVP Product Development; SVP Product Development & CAO; VP Research and Development; VP, Research & Dev't | 22 | 2007–2013 | |
| McPherson T. Alex | Director | 36 | 2007–2016 | ||
| Najafi Family Trust dated September 13, 2006 | Other; TenPercentOwner | 10 | 2007–2011 | ||
| Najafi Ramin | Director,OfficerOther; Director,Officer,TenPercentOwner; Director,Officer,TenPercentOwnerOther | CEO and President; Cheif Executive Officer; Chief Executive Officer | 43 | 2007–2015 | |
| O'Reilly John James | Director,Officer; Director,OfficerOther | CFO and SVP, Corporate Dev't; Chief Financial Officer; SVP Business and Corporate Dev | 4 | 2007–2011 | |
| Scott Colin | Officer | VP, Clinical Research and Dev; VP, Clinical Research and Deve; VP, Clinical Research & Dev't | 4 | 2007–2011 | |
| Tufts Robert R. | Director | 39 | 2007–2014 | person page Fuzzy | |
| Wicks Tony D.S. | Director | 36 | 2007–2015 | ||
| PAULSON THOMAS J | Officer | CFO; Chief Financial Officer | 30 | 2008–2017 | |
| HIXSON HARRY F JR | Director | 17 | 2009–2010 | person page Fuzzy | |
| WU ROY J | Officer | SVP Bus & Corp Development | 16 | 2009–2015 | |
| Anderson Mark Brian | Officer | CSO | 6 | 2009–2011 | |
| Maderis Gail J | Director | 13 | 2010–2019 | ||
| Stroman David W. | Officer | SVP, Ophthalmic Product Devt. | 14 | 2011–2015 | |
| Pioneer Pharma (Singapore) Pte. Ltd. | TenPercentOwner | 10 | 2012–2016 | ||
| NAQU AREA PIONEER PHARMA CO., LTD. | TenPercentOwner | 2 | 2012 | ||
| Li Xinzhou | Director,TenPercentOwner; TenPercentOwner; TenPercentOwnerOther | 11 | 2013–2021 | ||
| Bley Keith R | Officer | SVP Product Development | 5 | 2013–2014 | |
| China Pioneer Pharma Holdings Ltd | TenPercentOwner | 6 | 2013–2014 | ||
| Pioneer Pharma (Hong Kong) Co Ltd | TenPercentOwner | 4 | 2013–2019 | ||
| Radaelli Massimo | Director | 4 | 2014–2016 | ||
| SIECZKAREK MARK M | Director; Director,Officer; Other | CEO | 20 | 2014–2019 | |
| Hoon Russell A. | Officer | Senior Vice President | 3 | 2014–2015 | |
| Hall Justin | Director,Officer; Officer | CEO and GC; CEO, GC and Director; General Counsel; Interim President & CEO and GC; SVP, General Counsel | 11 | 2016–2022 | |
| LIU XIAOYAN | Director | 2 | 2016–2017 | ||
| WU MIJIA | Director | 14 | 2016–2024 | ||
| Fu Jian Ping | TenPercentOwner | 6 | 2016–2020 | ||
| Zavodnick Todd Erik | Director | 7 | 2016–2019 | ||
| Ma Yonghao | Director | 5 | 2016–2018 | ||
| McGovern John Joseph | Officer | CFO and Treasurer; Int Pres, CEO, CFO & Treasurer | 4 | 2017–2018 | |
| STUART LEWIS J | Officer | Chief Commercial Officer | 3 | 2018 | |
| Liu Yanbin | Director | 2 | 2018 | ||
| Raleigh Jason Philip | Officer | Interim CFO and Treasurer | 3 | 2019 | |
| Zheng Yenyou | Director | 9 | 2019–2026 | ||
| Wang Xiaopei | Director; Other | 3 | 2019–2020 | ||
| Sit Swan | Director | 9 | 2020–2026 | ||
| Xu Wang | Officer | NEO - Sr Mgr and Controller | 2 | 2020 | |
| Jones Andrew D. | Officer | CFO; CFO and Treasurer | 5 | 2020–2023 | |
| Kunin Audrey | Director,Officer; Officer | Chief Product Officer | 10 | 2021–2022 | |
| Kunin Jeffrey | Officer | President, DERMAdoctor, LLC | 10 | 2021–2022 | |
| Garlikov Julie | Director | 5 | 2022–2024 | ||
| Zheng Yongxiang | Director | 5 | 2022–2024 | ||
| Law Tommy | Officer | Chief Financial Officer; Interim CFO | 2 | 2023–2026 | |
| FAKHRY JAD | TenPercentOwner | 8 | 2025 | ||
| POPLAR POINT CAPITAL GP LLC | TenPercentOwner | 8 | 2025 | ||
| POPLAR POINT CAPITAL MANAGEMENT LLC | TenPercentOwner | 8 | 2025 | ||
| POPLAR POINT CAPITAL PARTNERS LP | TenPercentOwner | 8 | 2025 | ||
| Lazar David E. | Director,Officer,TenPercentOwner; TenPercentOwner | Chief Executive Officer | 3 | 2025–2026 | |
| Framework Ventures IV GP LLC | TenPercentOwner | 8 | 2025–2026 | ||
| Framework Ventures IV L.P. | TenPercentOwner | 8 | 2025–2026 | ||
| Framework Ventures Management LLC | TenPercentOwner | 8 | 2025–2026 | ||
| Kazley Michael John | Director,Officer,TenPercentOwner; TenPercentOwner | Chief Executive Officer | 13 | 2025–2026 | |
| R01 Capital LLC | TenPercentOwner | 6 | 2025–2026 | ||
| R01 Capital Manager LLC | TenPercentOwner | 6 | 2025–2026 | ||
| R01 Fund LP | Director,Officer,TenPercentOwner; TenPercentOwner | Chief Executive Officer | 6 | 2025–2026 | |
| Spencer Vance | TenPercentOwner | 8 | 2025–2026 | ||
| Anderson Michael Ernest | TenPercentOwner | 6 | 2025–2026 | ||
| Blynn Henry | Officer | Chief Operating Officer | 1 | 2026 | |
| Rios David Garcia | Director | 1 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2026-01-27 | NovaBay Pharmaceuticals, Inc. | Other | $134,000,000 | $134,000,000 | 4 | 1 |
| 2024-06-28 | NovaBay Pharmaceuticals, Inc. | Pharmaceuticals | $225,953 | $225,953 | 5 | 1 |
| 2024-04-05 | NovaBay Pharmaceuticals, Inc. | Pharmaceuticals | $665,000 | $665,000 | 5 | 1 |
| 2024-01-04 | NovaBay Pharmaceuticals, Inc. | Pharmaceuticals | $554,808 | $554,808 | 5 | 1 |
| 2023-05-18 | NovaBay Pharmaceuticals, Inc. | Pharmaceuticals | $3,000,000 | $3,000,000 | 5 | 1 |
| 2022-09-23 | NovaBay Pharmaceuticals, Inc. | Pharmaceuticals | $2,065,500 | $2,065,500 | 9 | 1 |
| 2022-09-23 | NovaBay Pharmaceuticals, Inc. | Pharmaceuticals | $3,250,000 | $3,250,000 | 4 | 1 |
| 2021-11-17 | NovaBay Pharmaceuticals, Inc. | Pharmaceuticals | $15,000,000 | $15,000,000 | 7 | 1 |
| 2020-07-31 | NovaBay Pharmaceuticals, Inc. | Pharmaceuticals | $6,829,580 | $0 | 0 | 1 |
| 2020-05-22 | NovaBay Pharmaceuticals, Inc. | Pharmaceuticals | $1,731,030 | $1,030 | 0 | 1 |
| 2020-05-01 | NovaBay Pharmaceuticals, Inc. | Pharmaceuticals | Indefinite | $0 | 0 | 1 |
| 2019-08-26 | NovaBay Pharmaceuticals, Inc. | Pharmaceuticals | $2,700,000 | $2,700,000 | 3 | 1 |
| 2019-08-26 | NovaBay Pharmaceuticals, Inc. | Pharmaceuticals | $4,198,566 | $4,198,566 | 4 | 1 |
| 2019-07-03 | NovaBay Pharmaceuticals, Inc. | Pharmaceuticals | $2,400,000 | $2,400,000 | 3 | 1 |
| 2018-02-14 | NovaBay Pharmaceuticals, Inc. | Pharmaceuticals | $5,984,000 | $5,984,000 | 1 | 1 |
| 2016-05-20 | NovaBay Pharmaceuticals, Inc. | Pharmaceuticals | $11,791,000 | $7,791,000 | 9 | 1 |
| 2016-02-26 | NovaBay Pharmaceuticals, Inc. | Pharmaceuticals | $2,830,804 | $2,830,804 | 3 | 1 |
| 2015-03-19 | NovaBay Pharmaceuticals, Inc. | Pharmaceuticals | $26,582,871 | $26,582,871 | 21 | 2 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.